Google
KTTA — PASITHEA THERAPEUTICS CORP (Healthcare >> Biotechnology)
KTTA FAQ
What is KTTA's ROE?
PASITHEA THERAPEUTICS CORP reports a Return on Equity (ROE) of -36.00%.
What is KTTA's dividend yield?
PASITHEA THERAPEUTICS CORP offers a dividend yield of 0.00%.
What is KTTA's Deepscope Quality Score?
Deepscope rates KTTA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy KTTA?
Deepscope's AI Timing Score for KTTA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does KTTA belong to?
PASITHEA THERAPEUTICS CORP is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.64
Price
-0.01
(-1.05%)
Day Change
|
|
|---|
KTTA, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.64 |
| PBV / Sector |
0.39 / 4.48
GREAT
|
| Earning Per Share | -0.58 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.30 M
GREAT
|
| Average 1W Daily Value |
0.72 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:15 |
| Symbol | KTTA |
| Name | PASITHEA THERAPEUTICS CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 33.41 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 21.55 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1111 Lincoln Road, Miami Beach, FL, United States, 33139
Phone: 786 977 3380
Website: https://www.pasithea.com
Sector: Healthcare >> Biotechnology
Description: Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
